Article -> Article Details
| Title | Anti-Obesity Drugs Market Size, Trends, Industry Share and Forecast Report 2026-2034 |
|---|---|
| Category | Fitness Health --> Health Articles |
| Meta Keywords | Anti-Obesity Drugs Market |
| Owner | akshaykumar |
| Description | |
| Market Overview The global anti-obesity drugs
market was valued at USD 2.7 Billion in 2025 and is projected to reach USD
6.4 Billion by 2034, growing at a CAGR of 9.50% during the forecast period
2026-2034. The market growth is driven by rising obesity rates, increasing
health awareness, advancements in drug development, government initiatives, and
expanding access to weight management treatments. North America dominates with
a substantial market share due to high obesity prevalence and robust healthcare
infrastructure. Study Assumption Years
Anti-Obesity Drugs Market Key Takeaways
Sample Request Link: https://www.imarcgroup.com/anti-obesity-drugs-market/requestsample Market Growth Factors The regional and global anti-obesity drugs market is driven
by an increase in the prevalence of obesity, the growing health consciousness
amongst consumers, and the demand for weight
management drugs. Long-term use of weight-loss medication that reduces appetite
and alters the metabolism is
emerging as a trend worldwide. R&D investment by drug companies focused on
new discoveries with better efficacy and safety, and government actions and approval have been
some of the main factors accelerating growth of the anti-obesity market. Another major driver has been the
common acceptance and availability of GLP-1 receptor agonists such as
semaglutide (Wegovy) and tirzepatide (Zepbound). These drugs have been studied in clinical
trials and found to reduce weight by 15% to 22% over 1 year. The increasing use
of prescribed combination therapy by physicians, which consist of more than one
centrally acting agent, and development of more effective and easy-to-use
products by manufacturers drive the market growth. The market is also benefitting from a trend toward oral
anti-obesity medications. Oral GLP-1 receptor agonists have the same mechanism
of action as those administered via subcutaneous injection, but have the added
benefit of being more convenient and preferred by patients who are reluctant to
receive injections. Insurance coverage and reimbursement for weight-loss
medications can help, and
are steadily expanding. In the United States, coverage for weight-loss
medications was provided by 44%
of U.S. employers with 500 or more employees in 2024, up from 41% in 2023. The
increasing recognition of obesity as a chronic disease that needs medical
attention, coupled with more insurance coverage and government-backed obesity
treatment campaigns, will
further drive market growth. Market Segmentation By Drug Class:
By Drug Type:
By Distribution Channel:
Regional Insights North America leads the anti-obesity drugs market with a
36.7% share in 2025, driven by high obesity prevalence (over 40% of adults in
the U.S. obese), advanced healthcare infrastructure, increasing adoption of
weight-loss medications, and favorable reimbursement policies. The U.S. and
Canada have strong governmental support, active R&D by major pharmaceutical
companies, and widespread consumer awareness, consolidating the region's
dominant position. Recent Developments & News
Key Players
If you require any specific information that is not
covered currently within the scope of the report, we will provide the same as a
part of the customization. Request For Customization: https://www.imarcgroup.com/request?type=report&id=5544&flag=E About Us IMARC Group is a global management consulting firm that
helps the world’s most ambitious changemakers to create a lasting impact. The
company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies,
company incorporation assistance, factory setup support, regulatory approvals
and licensing navigation, branding, marketing and sales strategies, competitive
landscape and benchmarking analyses, pricing and cost research, and procurement
research. Contact Us IMARC Group, 134 N 4th St. Brooklyn, NY 11249, USA, Email: sales@imarcgroup.com, Tel No: (D) +91 120 433 0800, United States: +1-201971-6302 | |